Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10011564 | 0.83 | SNCA (0.44) | SNCAALDH1A1CYP3A4HIF1AAPP | |
| Bromide SCHEMBL8447839 | 0.83 | SNCA (0.46) | SNCAALDH1A1CYP3A4HIF1AAPP | |
| Hydrochloric Acid SCHEMBL5973297 | 0.80 | SNCA (0.44) | SNCAALDH1A1CYP3A4HIF1AAPP | |
| Bromide SCHEMBL4434122 | 0.80 | SIGMAR1 (0.38) | SNCAALDH1A1 | |
| SCHEMBL3540870 | 0.78 | LTA4H (0.49) | — | |
| SCHEMBL11957421 | 0.78 | MAOB (0.47) | — | |
| SCHEMBL754087 | 0.78 | TRPA1 (0.41) | ALDH1A1 | |
| SCHEMBL20954586 | 0.77 | BCHE (0.46) | ALDH1A1 | |
| SCHEMBL704145 | 0.77 | CA4 (0.37) | ALDH1A1 | |
| SCHEMBL25255096 | 0.75 | TAAR1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | claimed |
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | disclosed |
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | NATIONAL INSTITUTES OF HEALTH | 2005-10-27 | — | — | US | disclosed |
| WO-2003086414-A1 | STRUCTURAL MODIFICATION OF RESVERATROL: SODIUM RESVERASTATIN PHOSPHATE | ARIZONA BOARD OF REGENTS (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240062-A1 | Structural modification of resveratrol: Sodium resverastatin phosphate | PI4KB, HDAC4, PIK3CA | SNCA 4520/4885ALDH1A1 3559/4885CYP3A4 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.